TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Hyphens Pharma International Ltd. ( (SG:1J5) ) has issued an announcement.
Hyphens Pharma has launched Winlevi®, a novel topical acne treatment, in Singapore and Malaysia, marking its first entry into Southeast Asia. This launch, facilitated by an exclusive agreement with Cassiopea S.p.A., represents a strategic expansion in the dermatology space, with plans to introduce the product in other Southeast Asian markets. Winlevi® is notable for its unique mechanism targeting the androgen-sebum pathway, offering a safe treatment option for acne without systemic side effects.
The most recent analyst rating on (SG:1J5) stock is a Buy with a S$0.40 price target. To see the full list of analyst forecasts on Hyphens Pharma International Ltd. stock, see the SG:1J5 Stock Forecast page.
More about Hyphens Pharma International Ltd.
Hyphens Pharma International Ltd. is Singapore’s leading specialty pharmaceutical and consumer healthcare group, focusing on expanding its presence in the dermatology sector.
Average Trading Volume: 75,076
Technical Sentiment Signal: Buy
Current Market Cap: S$100.5M
See more insights into 1J5 stock on TipRanks’ Stock Analysis page.